Clinical evaluation of fleroxacin in the treatment of bone and joint infections

Y. C. Liu, D. L. Cheng, C. Y. Liu, S. T. De Garis, H. H. Lin, T. L. Hsieh, M. Y. Yen, R. S. Wang, Y. S. Chen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8%) had osteomyelitis and 12 (63.2%) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7%) with osteomyelitis and in 8 of 11 patients (72.11%) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7% and 80.0%, respectively. The clinical response was cure in 4 of 7 patients (57.1%) evaluable for osteomyelitis, and in 9 of 12 patients (75.0%) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.

Original languageEnglish
Pages (from-to)514-519
Number of pages6
JournalSoutheast Asian Journal of Tropical Medicine and Public Health
Volume23
Issue number3
Publication statusPublished - 1992
Externally publishedYes

Fingerprint

Fleroxacin
Infectious Arthritis
Osteomyelitis
Joints
Bone and Bones
Infection
Therapeutics
Safety
Salmonella enteritidis
Staphylococcus aureus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Liu, Y. C., Cheng, D. L., Liu, C. Y., De Garis, S. T., Lin, H. H., Hsieh, T. L., ... Chen, Y. S. (1992). Clinical evaluation of fleroxacin in the treatment of bone and joint infections. Southeast Asian Journal of Tropical Medicine and Public Health, 23(3), 514-519.

Clinical evaluation of fleroxacin in the treatment of bone and joint infections. / Liu, Y. C.; Cheng, D. L.; Liu, C. Y.; De Garis, S. T.; Lin, H. H.; Hsieh, T. L.; Yen, M. Y.; Wang, R. S.; Chen, Y. S.

In: Southeast Asian Journal of Tropical Medicine and Public Health, Vol. 23, No. 3, 1992, p. 514-519.

Research output: Contribution to journalArticle

Liu, YC, Cheng, DL, Liu, CY, De Garis, ST, Lin, HH, Hsieh, TL, Yen, MY, Wang, RS & Chen, YS 1992, 'Clinical evaluation of fleroxacin in the treatment of bone and joint infections', Southeast Asian Journal of Tropical Medicine and Public Health, vol. 23, no. 3, pp. 514-519.
Liu, Y. C. ; Cheng, D. L. ; Liu, C. Y. ; De Garis, S. T. ; Lin, H. H. ; Hsieh, T. L. ; Yen, M. Y. ; Wang, R. S. ; Chen, Y. S. / Clinical evaluation of fleroxacin in the treatment of bone and joint infections. In: Southeast Asian Journal of Tropical Medicine and Public Health. 1992 ; Vol. 23, No. 3. pp. 514-519.
@article{78475e4e147f401aa5414c9193f93205,
title = "Clinical evaluation of fleroxacin in the treatment of bone and joint infections",
abstract = "The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8{\%}) had osteomyelitis and 12 (63.2{\%}) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7{\%}) with osteomyelitis and in 8 of 11 patients (72.11{\%}) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7{\%} and 80.0{\%}, respectively. The clinical response was cure in 4 of 7 patients (57.1{\%}) evaluable for osteomyelitis, and in 9 of 12 patients (75.0{\%}) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.",
author = "Liu, {Y. C.} and Cheng, {D. L.} and Liu, {C. Y.} and {De Garis}, {S. T.} and Lin, {H. H.} and Hsieh, {T. L.} and Yen, {M. Y.} and Wang, {R. S.} and Chen, {Y. S.}",
year = "1992",
language = "English",
volume = "23",
pages = "514--519",
journal = "Southeast Asian Journal of Tropical Medicine and Public Health",
issn = "0125-1562",
publisher = "Southeast Asian Ministers of Education Organisation",
number = "3",

}

TY - JOUR

T1 - Clinical evaluation of fleroxacin in the treatment of bone and joint infections

AU - Liu, Y. C.

AU - Cheng, D. L.

AU - Liu, C. Y.

AU - De Garis, S. T.

AU - Lin, H. H.

AU - Hsieh, T. L.

AU - Yen, M. Y.

AU - Wang, R. S.

AU - Chen, Y. S.

PY - 1992

Y1 - 1992

N2 - The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8%) had osteomyelitis and 12 (63.2%) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7%) with osteomyelitis and in 8 of 11 patients (72.11%) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7% and 80.0%, respectively. The clinical response was cure in 4 of 7 patients (57.1%) evaluable for osteomyelitis, and in 9 of 12 patients (75.0%) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.

AB - The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8%) had osteomyelitis and 12 (63.2%) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7%) with osteomyelitis and in 8 of 11 patients (72.11%) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7% and 80.0%, respectively. The clinical response was cure in 4 of 7 patients (57.1%) evaluable for osteomyelitis, and in 9 of 12 patients (75.0%) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.

UR - http://www.scopus.com/inward/record.url?scp=0027062759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027062759&partnerID=8YFLogxK

M3 - Article

C2 - 1488710

AN - SCOPUS:0027062759

VL - 23

SP - 514

EP - 519

JO - Southeast Asian Journal of Tropical Medicine and Public Health

JF - Southeast Asian Journal of Tropical Medicine and Public Health

SN - 0125-1562

IS - 3

ER -